| |
The awards are in recognition of innovation and excellence that recipient companies, teams and individuals have shown amid ongoing global economic uncertainty.
"It is gratifying to see that MDxHealth, and the hard work and dedication of our employees, has been recognized by Corporate LiveWire," noted Dr. Jan Groen, CEO of MDxHealth. "The increased adoption of ConfirmMDx® for Prostate Cancer within the U.S. urology community, together with two other commercialized cancer tests based on our proprietary technology, has established MDxHealth as a market leader in the important and growing field of cancer epigenetics. Our ability to deliver cancer diagnostics, which provide actionable information to help doctors make more informed treatment decisions, can significantly improve patient outcomes. We are proud to be making a difference."
The Corporate LiveWire judges assess resilience, creativity and the ability to adapt within the ever-changing environments of the respective fields. The judging panel considered the strengths of each nominee, focusing on the most innovative, groundbreaking and client-focused firms, teams and individuals who transformed the way they do business to succeed in a dynamic market. Each winner was awarded based on merit; demonstrating excellence, innovation and strong leadership across various activities over the past calendar year.
In addition to MDxHealth, this year's winners include: deVere Group for Excellence in Independent Financial Advice, Cendyn, Chaturvedi & Shah, J. Knipper & Co, Spar Group, GCL New Energy Holdings, LinkedIn, Google, Deloitte and PwC. The full winners guide can be found at: corporatelivewire.com/innovation-and-excellence-awards.html
About MDxHealth
MDxHealth (mdxhealth.com) is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.
Contact: Mike Sinclair - Halsin Partners
T: +44(0)20 7318 2955 / C: +44(0)79 6802 2075
E: msinclair[.]halsin.com.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
|
info[.]mdxhealth.com 
